Inhibikase Therapeutics, Inc. (IKT)

0.7200 +0.0045 (+0.63%) At close: 04:00PM EDT

Inhibikase Therapeutics, Inc.

3350 Riverwood Parkway SE
Suite 1900
Atlanta, GA 30339
United States
678-392-3419
https://www.inhibikase.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Milton H. Werner Ph.D.	CEO, Pres & Director	517.94k	N/A	1964
Mr. Joseph Frattaroli CPA	Chief Financial Officer	395.83k	N/A	1962
Dr. Roger Rush	Head of Preclinical Research	N/A	N/A	N/A
Dr. Surendra Singh	Head of Chemistry, Manufacturing & Controls	N/A	N/A	N/A
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D.	Medical Consultant, CEO of Clintrex Research Corp. & Science Advisor	N/A	N/A	N/A
Dan Williams	Controller	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor to treat Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. It has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Corporate governance

Inhibikase Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.